Curvebeam Ai Ltd. · ASX:CVB
Curvebeam Ai — Q1 FY24 Earnings Presentation
8 slides from Curvebeam Ai's earnings presentation, Oct 30, 2023
Slide 1: Quarterly 4C Conference Call
QUARTERLY 4C CONFERENCE CALL October 2023
Slide 2: Disclaimer
DISCLAIMER Introduction THIS DOCUMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, Forward looking statements DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA OR TO ANY The information given in this presentation is given for illustrative purposes only
Slide 3: 4C Reporting Definitions
4C REPORTING DEFINITIONS v Purchase order – a signed purchase order (PO) for a CT scanner (device). The Company considers POs to be the key metric as it reflects actual sales at the time a sale is completed. v Receipts from customers – any cash consideration received from a customer by CurveBeam AI.
Slide 4: 4C Highlights
4C HIGHLIGHTS • Foot & Ankle division of Stryker continues to build a strong sales pipeline • Received 4 purchase orders for HiRise™ devices in Q1 FY24 • A 100% increase on the prior corresponding period of 2 purchase orders in FY23 • 3 orders with Stryker – one financed deal • Directors believe Com
Slide 5: American Orthopedic Foot & Ankle Society (AOFAS) Annual Meeting
AMERICAN ORTHOPEDIC FOOT & ANKLE SOCIETY(AOFAS) ANNUAL MEETING AOFAS CONFERENCE – 20TH TO 23RD SEPTEMBER 2023 • Management attended conference to see firsthand reactions to HiRise™ • A very positive experience to see the responses from both Stryker representatives, surgeons & group surgeon practice
Slide 6: Enhanced HiRise Project
ENHANCED HIRISE™ PROJECT STRYKER CORPORATION - FOOT & ANKLE DIVISION • CurveBeam AI is developing enhancements to the HiRise™ platform, including a stronger X-Ray source for larger patients. • This will enable higher resolution scans of the hip & knee joints required for key surgical systems & patie
Slide 7: BMD HiRise Module Progress
BMD HIRISE™ MODULE PROGRESS • The BMD module is targeting a key annuity stream for sales & profit growth HiRise™ a change • The new enhanced HiRise™ platform is needed for the BMD Module agent • Patient data will be collected from April 2024 to support the 510(k) submission with devices to be placed
Slide 8: In Closing
IN CLOSING • Deploying IPO capital Q1 to support HiRise™ placements for FY24. • FY24 orders – Company remains very confident in purchase orders. • Directors believe Company from IPO has cash to carry out stated goals for 24 months. • Advancing enhanced HiRise™ platform for robotic system datasets to